Table 1.
Role of PI3K/AKT in regulation of EMT process during CRC progression
| Study | Year | Axis | Effect on the EMT | Samples | Clinical application |
|---|---|---|---|---|---|
| Wei [17] | 2019 | FAT4/PI3K/AKT/GSK-3B | Induced EMT |
100 T 100Na HCT116, LOVO and SW480 cell lines Xenograft model |
Therapeutic |
| Tan [27] | 2017 | PI3K/AKT/WDR5 | Induced EMT |
161 T 161N HT-29, SW620, HCT-15, HCT116, and COLO205 cell lines Xenograft model |
Therapeutic and prognostic |
| Pan [29] | 2020 | miR-328–3p/ Girdin/AKT | Suppressed EMT |
HCT116 and SW620 cell lines Xenograft model |
Therapeutic |
| Gao [30] | 2022 | MOR/AKT | Induced EMT |
180 T 180N HCT116, Caco-2, SW480, and LoVo cell lines |
Therapeutic and prognostic |
| Liu [31] | 2022 | CENPO/AKT | Induced EMT |
100 T 100N HCT116 and RKO cell lines Xenograft model |
Therapeutic and prognostic |
| Yang [32] | 2018 | GLI1/PI3K/AKT/NF-KB | Induced EMT |
109 T 35N HT29 and HCT116 cell lines |
Therapeutic |
| Zhang [33] | 2021 | PI3K/AKT/AGR2 | Induced EMT |
LoVo, SW480, HT-29, DLD-1, SW48 and HCT116 cell lines Xenograft model |
Therapeutic |
| Li [34] | 2020 | UCHL3/AKT/SOX12 | Induced EMT |
8 T 8N Lim1215, DLD1, SW48, HCT116, SW620, and SW480 cell lines Xenograft model |
Therapeutic and prognostic |
| Chen [35] | 2021 | MYSM1/PI3K/AKT | Suppressed EMT |
41 T 41N SW620 and LOVO cell lines Xenograft model |
Therapeutic and prognostic |
| Golhati [36] | 2011 | mTORC/Rac1/RhoA | Suppressed EMT |
18 T 18 M 18N HCT116, SW480 and KM20 cell lines Xenograft model |
Therapeutic |
| Cui [37] | 2019 | TTN-AS1/ miR-497 | Induced EMT |
95 T 95N SW480, SW620, HT29, HCT116 cell lines Xenograft model |
Therapeutic and prognostic |
| Liao [38] | 2022 | KIFC3/PI3K/AKT/mTOR | Induced EMT |
HT29, HCT116, SW480, DLD-1 cell lines Xenograft model |
Therapeutic |
| Duan [39] | 2018 | IMPDH2/AKT/mTOR/FOXO1 | Induced EMT |
248 T 248N HCT116, SW620, M5, SW480, HT29, DLD-1 and LoVo cell lines Xenograft model |
Therapeutic and prognostic |
| Xu [40] | 2020 | LACTB/AKT/mTOR | Induced EMT |
80 T 80N LOVO, SW480 and HCT116 cell lines Xenograft model |
Therapeutic and prognostic |
| Li [41] | 2022 | GREM1/PI3K/AKT/mTOR | Induced EMT |
55 T 55N SW480 and HCT116 cell lines Xenograft model |
Therapeutic and prognostic |
| Long [42] | 2022 | ECM1/PI3K/AKT/GSK3B/SNAIL | Induced EMT |
75 T 70N NCM460, HCT116, HCT15, HT29, SW480, 293 T, and SW620 cell lines Xenograft model |
Therapeutic and prognostic |
| Zhang [43] | 2021 | P2X7R/AKT/GSK3B | Induced EMT |
SW620 and HCT116 cell lines Xenograft model |
Therapeutic |
| Zhao [44] | 2019 | CAPS1/PI3K/AKT/GSK3B | Induced EMT |
126 T 126N HT29, SW480, DLD1, and SW620 cell lines |
Therapeutic and prognostic |
| Yu [45] | 2021 | CDX2PTEN/PI3K | Suppressed EMT |
161 T 161N RKO, Caco-2, HT-29, SW480 and Lovo cell lines Xenograft model |
Therapeutic and prognostic |
| Shen [46] | 2017 | CXCL8/PI3K/AKT/NF-KB | Induced EMT |
LoVo cell line Xenograft model |
Therapeutic |
| Cheng [47] | 2014 | CXCL8/ PI3K/AKT | Induced EMT |
213 T 213N SW480 and Caco-2 cell lines |
Therapeutic |
| Gao [48] | 2019 | CCR7/PI3K/AKT | Induced EMT |
190 T 190N HCT116, Caco-2, DLD-1, SW620, SW480, HT-29 and LoVo cell lines |
Therapeutic and prognostic |
| Wang [49] | 2020 | miR425-5p, miR-130b-3p, and miR-25-3p/ PTEN | Induced EMT |
17 T 12N HCT116 and SW620 cell lines Xenograft model |
Therapeutic |
| Wei [50] | 2019 | CCL22/PI3K/AKT | Induced EMT |
68 T 68N DLD1 and HT29 cell lines |
Therapeutic and prognostic |
| Chen [51] | 2021 | Id4/PI3K/AKT | Induced EMT |
HCT116 cell line Xenograft model |
Therapeutic |
| Yu [52] | 2019 | GATA1/AKT | Suppressed EMT |
74 T 74N HCT-116 and HCT-8 cell lines Xenograft model |
Therapeutic and prognostic |
| Zhang [53] | 2020 | miR-758/ PAX6 | Suppressed EMT |
84 T 84N HCT-116 and SW620 cell lines |
Therapeutic and prognostic |
| Cong [54] | 2019 | miR-760/ FOXA1 | Suppressed EMT |
54 T 54N SW620, HT29, DLD1 and HCT116 cell lines |
Therapeutic and prognostic |
| Miller [55] | 2020 | LSD1/AKT | Induced EMT | HT29, SW480, HCT116, LoVo and RKO cell lines | Therapeutic |
| Zhao [56] | 2016 | SPOCK1/PI3K/AKT | Suppressed EMT |
HCT116, HT29, SW480, and Lovo cell lines Xenograft model |
Therapeutic |
| Chen [57] | 2016 | STC2/PI3K/AKT | Induced EMT |
77 T 77N HT29 cell line Xenograft model |
Therapeutic and prognostic |
| Chen [58] | 2019 | CLCA4/PI3K/AKT | Induced EMT |
64 T 64N SW620 and LoVo cell lines |
Therapeutic and prognostic |
aTumor (T) tissues, Normal (N) margins